Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Elite Pharmaceuticals Inc ELTP

Healthcare
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug... see more

Recent & Breaking News (OTCQB:ELTP)

Brendan O'Brien Named to Strategic Advisory Board of Provectus Biopharmaceuticals, Inc.

Accesswire May 6, 2014

FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment

Accesswire April 29, 2014

Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

GlobeNewswire April 22, 2014

Limitless Venture Group Settles $163,391 Note with Beaufort Capital Partners

Accesswire April 16, 2014

Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund

Accesswire April 15, 2014

Elite Pharmaceuticals, Inc. Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC

GlobeNewswire April 14, 2014

Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs

GlobeNewswire March 27, 2014

Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine

GlobeNewswire March 24, 2014

Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally

GlobeNewswire March 10, 2014

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200

GlobeNewswire March 5, 2014

BlackBerry May Power Ford's Future Generation Cars

Accesswire February 25, 2014

Forest Labs to be acquired by Actavis for $25 billion while Prana Biotech surges on drug results

Accesswire February 19, 2014

Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201

GlobeNewswire February 18, 2014

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014

GlobeNewswire February 14, 2014

Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014

GlobeNewswire February 10, 2014

TrendingWallStreet.com Introduces Research on PLUG, ERBB, ELTP, and ITUB

Accesswire February 5, 2014

TrendingWallStreet.com Releases Updates on RFMD, EZPW, GFOX, and ELTP

Accesswire January 30, 2014

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product

Globe Newswire January 14, 2014

Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201

Globe Newswire December 5, 2013

Elite Pharmaceuticals Announces Conversion of Treppel Bridge Loan to Convertible Note

Globe Newswire November 26, 2013